List of Excipients in Branded Drug ACETAMINOPHEN AND IBUPROFEN (NSAID)

Generic Drugs Containing ACETAMINOPHEN AND IBUPROFEN (NSAID)

Company	Ingredient	NDC	Excipient
RITE AID	acetaminophen and ibuprofen (nsaid)	11822-1131	CARNAUBA WAX
RITE AID	acetaminophen and ibuprofen (nsaid)	11822-1131	CELLULOSE, MICROCRYSTALLINE
RITE AID	acetaminophen and ibuprofen (nsaid)	11822-1131	CROSCARMELLOSE SODIUM

What are the Most Frequently-Used Excipients in ACETAMINOPHEN AND IBUPROFEN (NSAID)?

# Of NDCs	Excipient
3	CARNAUBA WAX
3	CELLULOSE, MICROCRYSTALLINE
3	CROSCARMELLOSE SODIUM

Acetaminophen and Ibuprofen Excipient Strategy and Commercial Opportunities

Last updated: September 11, 2026

Acetaminophen and ibuprofen combination products offer a strong OTC platform because they combine two established analgesics with different pharmacologic mechanisms. The commercial opportunity is largest in dual-action tablets, caplets, liquid suspensions, orally disintegrating products, sachets, and differentiated modified-release systems. Excipient selection determines dose uniformity, tablet size, dissolution, palatability, manufacturability, stability, and regulatory risk.

In the United States, the combination is positioned primarily as an OTC analgesic and antipyretic product. Advil Dual Action is a commercial example containing 250 mg acetaminophen and 125 mg ibuprofen per caplet.[1] The product is regulated within the FDA OTC framework rather than as a conventional biologic or biosimilar product. The core active ingredients are mature, low-cost, and widely available, so commercial differentiation depends on formulation, delivery, branding, packaging, price, and channel access.

What is the commercial rationale for combining acetaminophen and ibuprofen?

The combination targets pain and fever through complementary mechanisms. Acetaminophen provides analgesic and antipyretic activity, while ibuprofen is a nonsteroidal anti-inflammatory drug with analgesic, antipyretic, and anti-inflammatory effects.[2,3]

The combination can create several commercial advantages:

Commercial variable	Acetaminophen and ibuprofen combination opportunity
Consumer benefit	One product may replace separate dosing of two analgesics
Differentiation	Dual-action positioning against single-ingredient acetaminophen or ibuprofen
Dose architecture	Fixed-dose products, flexible dosing, or age-specific presentations
Retail placement	Pain, fever, cold-and-flu, travel, and family-health categories
Manufacturing	Conventional direct compression or wet granulation can support high-volume production
Margin opportunity	Low API cost allows premium pricing for convenience and delivery performance
Expansion	Tablets, liquids, chewables, orally disintegrating tablets, and sachets
Geographic reach	OTC markets, private-label products, and licensing in international markets

The combination also creates a dosing-convenience proposition. A fixed-dose product may reduce the need for consumers to purchase and administer two separate products. That proposition must be balanced against labeling requirements, contraindications, maximum daily doses, and the risk that consumers may unknowingly take additional acetaminophen- or ibuprofen-containing medicines.

What excipient strategy is suitable for acetaminophen and ibuprofen tablets?

A robust immediate-release tablet generally requires a separate solution for each API’s processing and dissolution characteristics. Acetaminophen has relatively high dose loading and can present compressibility and dissolution challenges. Ibuprofen is hydrophobic, has poor aqueous solubility, and may exhibit sticking or picking during compression.[4,5]

A typical excipient architecture is:

Excipient function	Candidate materials	Formulation purpose
Diluent	Microcrystalline cellulose, spray-dried lactose, mannitol, dibasic calcium phosphate	Controls tablet mass, flow, and compressibility
Binder	Povidone, copovidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Accelerates tablet breakup
Wetting or solubilizing aid	Sodium lauryl sulfate, poloxamer, surfactant blends	Improves ibuprofen wetting and dissolution
Glidant	Colloidal silicon dioxide	Improves powder flow
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces ejection force and tooling adhesion
Film coating	Hypromellose, polyvinyl alcohol, polyethylene glycol, titanium dioxide or approved colorants	Controls appearance, swallowability, and moisture protection
Taste masking	Polyols, flavors, sweeteners, ion-exchange resins, polymer coatings	Supports pediatric or chewable dosage forms

The principal formulation risk is that the excipient system must improve ibuprofen wetting without creating excessive lubrication or slowing acetaminophen dissolution. Magnesium stearate can impair wetting when overused or overmixed. Sodium stearyl fumarate may be considered where lower hydrophobicity or improved processing performance is required, although compatibility and tableting performance must be demonstrated.

Which excipients improve ibuprofen dissolution?

Ibuprofen dissolution can be improved through particle-size control, wetting agents, solid dispersions, surfactant-assisted granulation, alkaline microenvironments, or conversion to a more soluble ibuprofen salt. Conventional products usually rely on a combination of micronized API, disintegrant, wetting agent, and controlled compression force.

Potential approaches include:

1. Micronized ibuprofen with a surfactant-containing granulation system.
2. Amorphous solid dispersion using a polymer such as copovidone or hypromellose-based material.
3. Ibuprofen lysine or another salt form where the regulatory and labeling strategy permits a different active ingredient designation.
4. Effervescent or rapidly dispersible systems using bicarbonate and organic acids.
5. Lipid-based or self-emulsifying systems for liquid or softgel products.

Each approach changes the regulatory and intellectual-property profile. A simple micronization and excipient optimization strategy may have limited patent strength. A novel solid dispersion, salt, particle-engineering process, or delivery system may support stronger formulation claims.

What excipients are appropriate for pediatric acetaminophen and ibuprofen liquids?

Liquid products create a larger excipient opportunity because palatability and physical stability are central to consumer acceptance. Acetaminophen is commonly formulated in aqueous suspensions or solutions. Ibuprofen is less water-soluble and commonly requires a suspension system.

A pediatric suspension may use:

• Purified water as the vehicle.
• Glycerin, sorbitol, or propylene glycol for viscosity and mouthfeel.
• Microcrystalline cellulose and carboxymethylcellulose as a suspending system.
• Xanthan gum or other rheology modifiers.
• Polysorbate or another suitable wetting agent.
• Citrate or phosphate buffers for pH control.
• Sweeteners such as sucralose, sorbitol, or sucrose, subject to pediatric tolerability.
• Flavors selected to mask ibuprofen bitterness.
• Preservatives where justified by the multidose container and microbiological risk assessment.

The formulation must maintain dose uniformity after shaking, limit sedimentation and caking, and remain pourable across the labeled shelf life. Preservative selection must account for pH, container compatibility, antimicrobial effectiveness, and pediatric exposure.

Sugar-free and alcohol-free positioning can create a commercial advantage. High-polyol systems require attention to gastrointestinal tolerability. Artificial-color-free products may appeal to specific consumer segments but can narrow visual differentiation and complicate suspension appearance.

What dosage forms offer the strongest commercial opportunities?

Immediate-release caplets and tablets

Immediate-release caplets are the lowest-risk commercial platform. They support high-speed manufacturing, low packaging cost, and broad retail distribution. The main development variables are tablet size, dose uniformity, disintegration, dissolution, friability, and coating performance.

A bilayer tablet can separate acetaminophen and ibuprofen physically and allow independent control of granulation and dissolution. It may also support a distinctive product design, although bilayer equipment and process controls increase capital and manufacturing complexity.

Softgels

Softgels can improve swallowability and provide a premium format. Ibuprofen may be incorporated into a lipid vehicle, while acetaminophen presents a higher loading challenge. A dual-chamber or multiparticulate softgel could create differentiation but would increase manufacturing and stability complexity.

Chewable tablets

Chewables provide access to pediatric, adolescent, and adult consumers who have difficulty swallowing tablets. Ibuprofen’s bitterness and acetaminophen’s taste require effective flavor and taste-masking systems. Chewable products also need careful control of hardness, friability, mouthfeel, and dose uniformity.

Orally disintegrating tablets

An orally disintegrating tablet may target rapid administration without water. High drug loading can make tablet size and mechanical strength difficult. Mannitol, crospovidone, low-moisture excipients, and specialized compression processes may be appropriate. The product must demonstrate rapid disintegration without excessive friability.

Oral powders and sachets

Powder sachets enable portable dosing and can support effervescent or rapidly dispersible products. They also create opportunities for single-use packaging and flavored products. Moisture sensitivity, blend segregation, dose accuracy, and reconstitution behavior are key risks.

Topical or locally acting systems

Topical ibuprofen products are established in some markets, but adding acetaminophen creates a more complex pharmacologic and regulatory concept. The two APIs have different physicochemical properties and may not be suitable for the same topical delivery system. This is a higher-risk opportunity than oral fixed-dose products.

How strong is the patent estate for acetaminophen and ibuprofen combinations?

The active ingredients are old and generally cannot support new composition-of-matter exclusivity. Commercial protection is more likely to arise from:

• Fixed-dose ratios.
• Bilayer or multilayer tablet architecture.
• Specific dissolution profiles.
• Salt forms or particle-engineered APIs.
• Taste-masking systems.
• Pediatric suspension systems.
• Modified-release or pulsatile-release delivery.
• Packaging that improves stability or dosing accuracy.
• Manufacturing processes.
• Method-of-use claims for defined pain conditions or dosing schedules.

In the United States, OTC monograph products generally do not receive the same Orange Book-based patent framework as approved prescription products. FDA’s OTC monograph system establishes conditions for marketing covered nonprescription drugs, including active ingredients, indications, labeling, and dosage forms.[6] A product outside the monograph may require an NDA or other FDA pathway.

What patents protect formulation improvements?

The strongest formulation patents usually claim a measurable technical result rather than only a list of common excipients. Examples include:

• A defined dissolution profile at specified time points.
• A stable suspension with limited sedimentation and rapid redispersion.
• A taste-masked multiparticulate formulation.
• A bilayer tablet with controlled release from one layer.
• A solid dispersion that maintains supersaturation.
• A specific particle-size distribution and excipient ratio.
• A manufacturing process that reduces sticking or improves content uniformity.

Patent durability depends on claim scope, enablement, written description, prior-art exposure, and whether competitors can design around the claimed excipient percentages or process parameters.

When does acetaminophen and ibuprofen lose exclusivity?

The active ingredients have long been off-patent. There is no meaningful composition-of-matter exclusivity for conventional acetaminophen or ibuprofen products. Commercial exclusivity therefore depends on brand equity, regulatory status, formulation patents, trademarks, trade dress, supply contracts, and retail execution.

For a conventional OTC combination:

Exclusivity category	Practical position
API patent	Generally expired
New chemical entity exclusivity	Not applicable
Biosimilar exclusivity	Not applicable
Orange Book patent strategy	Usually not central for monograph OTC products
Formulation patents	Possible for novel delivery or stability systems
Trademark protection	Potentially important
Trade dress	Potentially important but narrower than patent protection
Retail exclusivity	Contractual and channel-specific
Regulatory exclusivity	Depends on the product’s FDA pathway

A Paragraph IV challenge is generally relevant to an approved NDA product with Orange Book-listed patents, not to a conventional OTC monograph product. If a novel prescription or NDA-approved acetaminophen/ibuprofen combination were marketed, Paragraph IV litigation could become relevant. For standard OTC products, competition typically enters through monograph compliance, private-label launches, and manufacturer substitution rather than an ANDA patent challenge.

What is the FDA regulatory status of acetaminophen and ibuprofen combinations?

Acetaminophen and ibuprofen are established OTC active ingredients, but a specific combination must comply with the applicable FDA requirements for active ingredients, indications, dosage, labeling, warnings, and manufacturing.[2,3,6]

Important regulatory issues include:

• Acetaminophen liver-toxicity warnings and maximum daily exposure.
• Ibuprofen gastrointestinal bleeding, cardiovascular, renal, and hypersensitivity warnings.
• Contraindications and warnings for pregnancy, especially late pregnancy for NSAIDs.
• Duplicate therapy risks from combination cold, flu, and pain products.
• Pediatric dosing and age restrictions.
• Dose uniformity and dissolution for solid products.
• Microbial quality and preservative performance for liquids.
• Stability under ICH conditions.
• Human factors for dosing devices and package labeling.

FDA has repeatedly required clearer acetaminophen labeling and warnings because consumers may take multiple acetaminophen-containing products simultaneously.[7] A combination product must make the presence and amount of both ingredients prominent in the principal display panel and Drug Facts labeling.

What manufacturing and IP barriers affect commercial entry?

The manufacturing barriers are moderate for immediate-release tablets and higher for differentiated formats.

Immediate-release products

Key manufacturing risks include:

• Segregation caused by differences in API density and particle size.
• Ibuprofen sticking during compression.
• Acetaminophen’s high dose load.
• Lubricant-related dissolution delays.
• Coating defects caused by tablet mass or surface characteristics.
• Cross-contamination controls in multiproduct facilities.

Liquid products

Liquid manufacturing requires validated suspension mixing, high-shear dispersion, deaeration, filling accuracy, preservative control, and container-closure compatibility. Device accuracy becomes important when the product uses oral syringes or dosing cups.

Softgels and multiparticulates

Softgels require specialized encapsulation capacity, gelatin or non-gelatin shell control, fill-shell compatibility, and longer development timelines. Multiparticulates can improve taste masking and dose flexibility but require more complex coating and blend-uniformity controls.

IP barriers are strongest where the product uses a proprietary delivery technology or a difficult-to-replicate process. Common excipient combinations alone usually provide limited freedom-to-operate protection unless linked to a novel performance profile.

Which companies are competing in acetaminophen and ibuprofen combinations?

The competitive field includes branded OTC manufacturers, generic drug companies, private-label retailers, and contract development and manufacturing organizations.

Competitor type	Representative commercial position
Branded OTC manufacturers	Dual-action pain products, premium packaging, national advertising
Generic manufacturers	Lower-cost tablets, caplets, and liquids
Retail private labels	Store-brand equivalents with price-based competition
International manufacturers	Local combinations with different dose ratios and dosage forms
CDMOs	Formulation development, scale-up, packaging, and private-label supply
Specialty innovators	Fast-dissolve, pediatric, effervescent, or modified-release products

A potential licensee may value a platform that provides differentiated dissolution, better taste masking, reduced tablet size, longer shelf life, or a proprietary pediatric delivery system. Licensing economics will depend on whether the technology is protected by issued patents, has demonstrated commercial-scale manufacture, and avoids regulatory reclassification.

How does acetaminophen and ibuprofen compare with other pain products?

Product	Primary commercial advantage	Main limitation
Acetaminophen alone	Broad consumer familiarity and low GI risk relative to NSAIDs	Liver-toxicity risk at excessive doses; limited anti-inflammatory effect
Ibuprofen alone	Anti-inflammatory activity and established OTC demand	GI, renal, cardiovascular, and pregnancy-related warnings
Acetaminophen plus ibuprofen	Dual-action positioning and dosing convenience	More complex warnings and duplicate-therapy risk
Acetaminophen plus aspirin plus caffeine	Established headache positioning	Aspirin bleeding risk and caffeine sensitivity
Naproxen	Longer dosing interval	NSAID safety profile and slower onset for some consumers
Topical NSAIDs	Lower systemic exposure potential	Localized use and formulation constraints

The combination has the clearest commercial logic in acute pain, dental pain, musculoskeletal pain, headache, and fever categories. Claims must remain consistent with the applicable regulatory pathway and approved or monograph-supported labeling.

What are the highest-value commercial opportunities?

The strongest opportunities are:

1. A lower-tablet-size caplet with fast, reliable dissolution.
2. A sugar-free pediatric suspension with superior taste and redispersion.
3. A chewable product for adolescents and adults with swallowing difficulty.
4. A single-dose sachet for travel, sports, and workplace use.
5. A private-label platform with multiple dose strengths and packaging configurations.
6. A bilayer tablet with independent API processing and differentiated dissolution.
7. A premium product with child-resistant, senior-friendly packaging and clear duplicate-therapy warnings.
8. A formulation licensed to regional OTC manufacturers in markets where dual-action products are underdeveloped.

Revenue exposure is most sensitive to retail distribution, price-per-dose, repeat purchase, and the ability to preserve a premium over generic single-ingredient products. The APIs themselves are inexpensive. Value is created through formulation performance, consumer convenience, brand trust, and supply reliability.

Key Takeaways

• Acetaminophen and ibuprofen are mature APIs with limited active-ingredient patent value.
• The commercial opportunity is concentrated in formulation, delivery, packaging, and brand differentiation.
• Ibuprofen wetting and dissolution are the central solid-dose formulation challenges.
• Acetaminophen creates high tablet-load and content-uniformity demands.
• Pediatric liquids offer substantial differentiation through taste masking, suspension stability, and dosing-device design.
• Conventional OTC monograph products generally do not rely on Orange Book patent exclusivity or Paragraph IV litigation.
• Stronger patent positions require measurable performance advantages, novel delivery systems, or difficult-to-replicate manufacturing processes.
• The most scalable opportunities are immediate-release caplets, private-label platforms, pediatric suspensions, chewables, and sachets.
• FDA labeling must address liver, gastrointestinal, renal, cardiovascular, pregnancy, and duplicate-therapy risks.
• Biosimilar competition is not relevant because acetaminophen and ibuprofen are small-molecule drugs, not biologics.

FAQs

Can acetaminophen and ibuprofen be formulated in one immediate-release tablet?

Yes. The combination can be manufactured as a conventional tablet or caplet, but the excipient system must balance acetaminophen loading, ibuprofen wetting, tablet strength, disintegration, and dissolution.

Is a bilayer acetaminophen and ibuprofen tablet commercially attractive?

Yes, where separate API processing or differentiated dissolution provides a consumer or manufacturing advantage. The format adds equipment, validation, and scale-up complexity.

Can a company patent a new acetaminophen and ibuprofen ratio?

A ratio alone may face substantial prior-art risk. Patent strength improves when the ratio is tied to a novel clinical use, dosage regimen, delivery system, stability profile, or measurable dissolution advantage.

What is the main risk in pediatric acetaminophen and ibuprofen suspensions?

The main risks are poor taste, sedimentation, caking, inaccurate dosing, preservative failure, and consumer confusion about age-based dosing and duplicate active ingredients.

Are generic manufacturers likely to enter acetaminophen and ibuprofen combination products?

Yes. Generic and private-label entry is commercially feasible for conventional immediate-release products. Barriers increase for patented delivery systems, specialized dosage forms, proprietary suspension technologies, and complex manufacturing processes.

References

1. Haleon. (n.d.). Advil Dual Action with acetaminophen Drug Facts label. DailyMed, U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (n.d.). Acetaminophen. FDA.

3. U.S. Food and Drug Administration. (n.d.). Ibuprofen. FDA.

4. Aulton, M. E., & Taylor, K. M. G. (Eds.). (2018). Aulton’s pharmaceutics: The design and manufacture of medicines (5th ed.). Elsevier.

5. U.S. Pharmacopeia. (2023). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.

6. U.S. Food and Drug Administration. (2024). Over-the-counter monograph drugs. FDA.

7. U.S. Food and Drug Administration. (2011). Prescription combination drug products with acetaminophen: FDA statement and safety communications. FDA.